Boothbay Fund Management LLC Sells 29,362 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Boothbay Fund Management LLC lowered its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 27.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 76,865 shares of the biopharmaceutical company's stock after selling 29,362 shares during the period. Boothbay Fund Management LLC owned approximately 0.06% of Catalyst Pharmaceuticals worth $1,604,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in CPRX. JPMorgan Chase & Co. increased its holdings in shares of Catalyst Pharmaceuticals by 9.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company's stock worth $8,116,000 after purchasing an additional 33,888 shares in the last quarter. Farther Finance Advisors LLC raised its position in Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after buying an additional 1,495 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Catalyst Pharmaceuticals by 13.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company's stock valued at $8,710,000 after acquiring an additional 50,888 shares during the period. Redhawk Wealth Advisors Inc. purchased a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at about $1,273,000. Finally, Spire Wealth Management grew its stake in shares of Catalyst Pharmaceuticals by 1,342.9% in the fourth quarter. Spire Wealth Management now owns 14,429 shares of the biopharmaceutical company's stock worth $301,000 after acquiring an additional 13,429 shares during the period. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Trading Up 2.3 %

Shares of NASDAQ:CPRX traded up $0.57 during midday trading on Friday, reaching $24.84. 764,813 shares of the company were exchanged, compared to its average volume of 1,103,936. The stock has a market cap of $3.03 billion, a PE ratio of 21.05, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70. The business's fifty day moving average is $22.84 and its two-hundred day moving average is $22.33. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $26.16.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Robert W. Baird increased their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Monday, March 3rd. Bank of America restated a "buy" rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. HC Wainwright restated a "buy" rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Finally, Stephens reissued an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $32.29.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the transaction, the insider now directly owns 68,873 shares of the company's stock, valued at $1,521,404.57. The trade was a 39.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the sale, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.